Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 18, 2015 3:48 AM ET


Company Overview of CureVac GmbH

Company Overview

CureVac GmbH, a biopharmaceutical company, develops therapeutic messenger RNA vaccines for cancer and prophylactic vaccines for infectious diseases. The company provides RNActive molecules as immunotherapeutics for the treatment of cancer and as prophylactic vaccines against infectious diseases. It also develops adjuvants based on non-coding RNAs (RNAdjuvant) for enhancing the immune response of other vaccines. CureVac GmbH has strategic partnership with Janssen Pharmaceuticals, Inc. and Sanofi Pasteur S.A. The company was founded in 2000 and is based in Tubingen, Germany.

Paul-Ehrlich-Straße 15

Tubingen,  72076


Founded in 2000


49 70 71 9 20 53 100


49 70 71 9 20 53 101

Key Executives for CureVac GmbH

Founder, Chief Executive Officer, Managing Director and Head of Business Development
Co-Founder and Chief Operating Officer
Chief Corporate Officer
Chief Medical Officer
Head of Human Resources
Compensation as of Fiscal Year 2014.

CureVac GmbH Key Developments

CureVac GmbH Presents at BIO-Europe Spring 2015, Mar-10-2015 04:15 PM

CureVac GmbH Presents at BIO-Europe Spring 2015, Mar-10-2015 04:15 PM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Boehringer Ingelheim and CureVac Announce Collaboration to Develop Next Generation Lung Cancer Immunotherapy

Boehringer Ingelheim and CureVac jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer. Boehringer Ingelheim will start clinical investigation of CV9202 in at least two different lung cancer settings, in combination with afatinib in patients with advanced or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) and in combination with chemo-radiation therapy in patients with unresectable stage III NSCLC. CureVac receives EUR 35 million (approximately $45 million). Further, CureVac can achieve milestone payments of up to EUR 430 million (approximately $556 million) and royalties on sales. This new agreement is part of Boehringer Ingelheim's long-term commitment to delivering tomorrow's cancer therapies through the discovery of novel treatment options with high therapeutic value for patients. The company's oncology portfolio includes afatinib, a once-daily kinase inhibitor that irreversibly binds and inhibits ErbB1, ErbB2 and ErbB4 receptors and is approved in a number of markets including the EU and US. In the US, afatinib is marketed as Gilotrif(R) for the first-line treatment of common types of EGFR-mutation positive metastatic NSCLC (Del 19 or L858R). Boehringer Ingelheim's oncology pipeline covers a broad range of solid tumors and hematologic malignancies (blood cancer), including two investigational compounds in Phase III clinical development: nintedanib in NSCLC and colorectal cancer, and volasertib in acute myeloid leukemia. These compounds are not approved, and their safety and efficacy have not been established. CureVac's mRNA-based technology represents a potential novel approach in cancer treatment. For the first time mRNA could be optimized to mobilize the patient's own immune system to fight the tumor with a specific immune response elicited through the RNActive(R) vaccine. Cancer immunotherapy has been chosen as the "Breakthrough of the year 2013" by SCIENCE magazine. CV9202 is a combination of mRNA molecules coding for six antigens overexpressed in lung cancer, designed to induce an immune response against the tumor. CV9202 and the preceding RNActive(R) cancer vaccine CV9201 tested in initial clinical trials by CureVac demonstrated activity in generating immune responses against all anti-tumor antigens.

CureVac GmbH Presents at BIO-Europe 2014, Nov-04-2014 05:00 PM

CureVac GmbH Presents at BIO-Europe 2014, Nov-04-2014 05:00 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.

Similar Private Companies By Industry

Company Name Region
Temmler Pharma GmbH & Co. KG Europe
AVIE GmbH & Co. KG Europe
FOCUS Clinical Drug Development GmbH Europe
Orthogen Veterinary GmbH Europe

Recent Private Companies Transactions

Private Placement
March 5, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CureVac GmbH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at